Royal Bank of Canada Issues Pessimistic Forecast for Health Catalyst (NASDAQ:HCAT) Stock Price

Health Catalyst (NASDAQ:HCAT) had its price target cut by Royal Bank of Canada from $7.00 to $6.00 in a note issued to investors on Thursday,Benzinga reports. The firm presently has a “sector perform” rating on the stock. Royal Bank of Canada’s price target would indicate a potential upside of 28.48% from the stock’s current price.

HCAT has been the topic of several other reports. Stifel Nicolaus reduced their target price on Health Catalyst from $10.00 to $5.00 and set a “hold” rating on the stock in a report on Thursday. Stephens reaffirmed an “equal weight” rating and issued a $7.00 price objective on shares of Health Catalyst in a research note on Thursday. Citigroup decreased their price objective on shares of Health Catalyst from $10.50 to $10.00 and set a “buy” rating for the company in a research report on Friday, January 10th. KeyCorp upgraded shares of Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 target price on the stock in a report on Wednesday, January 8th. Finally, Piper Sandler decreased their price target on Health Catalyst from $12.00 to $8.00 and set an “overweight” rating for the company in a report on Tuesday, February 11th. Three analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, Health Catalyst has an average rating of “Moderate Buy” and an average price target of $9.45.

Health Catalyst Stock Up 6.4 %

Shares of NASDAQ:HCAT opened at $4.67 on Thursday. The firm has a market cap of $284.16 million, a P/E ratio of -3.46 and a beta of 1.34. Health Catalyst has a 12-month low of $3.76 and a 12-month high of $9.24. The business has a fifty day simple moving average of $5.98 and a 200 day simple moving average of $7.23. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32.

Insider Buying and Selling

In other news, insider Linda Llewelyn sold 6,441 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $5.43, for a total transaction of $34,974.63. Following the transaction, the insider now directly owns 85,819 shares of the company’s stock, valued at $465,997.17. This represents a 6.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Kevin Lee Freeman sold 7,500 shares of the stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $8.94, for a total value of $67,050.00. Following the completion of the transaction, the insider now owns 236,950 shares in the company, valued at approximately $2,118,333. This represents a 3.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 87,610 shares of company stock valued at $664,043. 2.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Health Catalyst

Hedge funds and other institutional investors have recently made changes to their positions in the business. Harbor Capital Advisors Inc. increased its holdings in Health Catalyst by 21.3% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 11,764 shares of the company’s stock worth $96,000 after purchasing an additional 2,064 shares in the last quarter. Group One Trading LLC boosted its position in shares of Health Catalyst by 107.6% during the fourth quarter. Group One Trading LLC now owns 4,360 shares of the company’s stock valued at $31,000 after buying an additional 2,260 shares during the last quarter. Creative Planning grew its holdings in Health Catalyst by 13.2% during the third quarter. Creative Planning now owns 21,348 shares of the company’s stock worth $174,000 after buying an additional 2,486 shares in the last quarter. Two Sigma Securities LLC raised its position in Health Catalyst by 19.5% in the 4th quarter. Two Sigma Securities LLC now owns 17,510 shares of the company’s stock valued at $124,000 after buying an additional 2,862 shares during the last quarter. Finally, Legato Capital Management LLC lifted its stake in Health Catalyst by 3.7% during the 4th quarter. Legato Capital Management LLC now owns 87,992 shares of the company’s stock valued at $622,000 after acquiring an additional 3,171 shares in the last quarter. 85.00% of the stock is owned by institutional investors.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.